rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BNP Blood Tests Predict Heart Damage From Cancer Chemotherapy

RPEP-006102000Okumura, H; Iuchi, K; Yoshida, T; Nakamura, S; Takeshima, M; Takamatsu, H; Ikeno, A; Usuda, K; Ishikawa, T; Ohtake, S; Matsuda, T
CohortModerate evidence
The takeaway

Persistent BNP elevation after anthracycline chemotherapy predicted the development of cardiotoxicity, making serial BNP monitoring a sensitive early warning system for chemotherapy-induced heart damage.

Persistent vs transient

Persistent BNP elevation after chemo predicted cardiotoxicity, while transient rises were benign — the pattern matters, not just the level

What the researchers found

Persistent BNP elevation after anthracycline chemotherapy predicted development of cardiotoxicity, distinguishing at-risk patients from those with only transient, benign BNP rises.

Why it matters

Anthracyclines are among the most effective cancer drugs, but heart damage limits their use. A blood test that predicts who will develop heart damage enables personalized dosing — maximizing cancer treatment while protecting the heart.

How the study worked

Prospective cohort study measuring serial plasma BNP before, during, and after anthracycline chemotherapy. BNP trajectories correlated with echocardiographic cardiac function and clinical cardiotoxicity endpoints.

What this study cannot tell us

Specific patient numbers and BNP cutoff values not detailed in abstract. Results may vary with different anthracycline regimens. Other biomarkers (troponin) also have predictive value.

How to read the evidence

Moderate evidence from a prospective cohort with serial biomarker monitoring and clinical outcome correlation.

When this study was published

Published in 2000. BNP/NT-proBNP monitoring during cardiotoxic chemotherapy is now recommended in multiple cardio-oncology guidelines.

The bigger picture

Cardio-oncology is one of medicine's most challenging balancing acts. BNP monitoring offers a practical, inexpensive way to navigate between effective cancer treatment and heart protection.

Questions still open

  • Should BNP monitoring be mandatory during anthracycline chemotherapy?
  • Can early intervention based on persistent BNP prevent irreversible cardiotoxicity?
  • Does combining BNP with troponin improve prediction?

Common questions

How common is heart damage from chemotherapy?
Anthracycline cardiotoxicity affects up to 10-20% of patients, depending on cumulative dose. It can cause permanent heart failure years after treatment, making early detection through BNP monitoring critically important.
What should patients know?
If your BNP stays elevated after chemotherapy (not just a brief spike), it may signal developing heart damage. Regular BNP monitoring can catch this early, allowing your doctor to modify treatment before permanent damage occurs.

Read the original research

Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.

Acta haematologica, 104(4), 158-63

View on PubMed ↗

Citation

Okumura, H; Iuchi, K; Yoshida, T; Nakamura, S; Takeshima, M; Takamatsu, H; Ikeno, A; Usuda, K; Ishikawa, T; Ohtake, S; Matsuda, T. (2000). Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.. Acta haematologica, 104(4), 158-63.